Two commonly prescribed cardiovascular medications were recalled by their manufacturers in early 2026 due to manufacturing defects that could reduce their effectiveness — creating a potential gap in protection for patients depending on these drugs to manage their cholesterol and cardiovascular disease risk.
The FDA classified both as Class II recalls — meaning the product involved "may cause temporary or medically reversible adverse health consequences" rather than posing an immediate life-threatening danger. In practice, this means the drugs may not work as effectively as they should, not that they are actively harmful to take.
The Rosuvastatin Recall (AvKARE)
According to FDA enforcement records and Fox Business reporting, AvKARE recalled Rosuvastatin Tablets, USP, 10 mg, packaged in 50-tablet unit-dose cartons.
- Lot number : 49124
- Expiration date : December 31, 2026
- Reason for recall : Out of specification for dissolution — the medication does not dissolve in the body as it is supposed to, meaning it may not be fully absorbed and therefore may not lower LDL cholesterol as effectively as intended
- Recall initiated : December 31, 2025
- Status : Ongoing
Rosuvastatin (brand name: Crestor) is one of the most widely prescribed statins in the United States, used to lower LDL cholesterol and reduce the risk of heart attack, stroke, and cardiovascular disease. A dissolution failure means patients taking the recalled lot may not receive the full LDL-lowering benefit, potentially leaving them at higher cardiovascular risk than their physician intends, particularly in the window during which they were taking the affected product.
The Icosapent Ethyl Recall (Zydus)
According to the same FDA reporting, Zydus Pharmaceuticals (USA) Inc. recalled Icosapent Ethyl capsules, 1 gram, distributed in 120-count bottles.
- Affected lots : S2520304, S2520333, and S2540186
- Expiration dates : 2027
- Bottles affected : Approximately 22,896
- Reason for recall : Subpotency caused by oxidation from capsule leakage — the active ingredient has degraded due to oxygen exposure, reducing the drug's therapeutic concentration
- Recall initiated : December 30, 2025
- Status : Ongoing
Icosapent ethyl (brand name: Vascepa) is a purified omega-3 fatty acid (EPA) approved to reduce triglyceride levels and, based on the REDUCE-IT trial, to reduce cardiovascular events in patients with elevated triglycerides who are already on statin therapy. Its cardiovascular benefit depends on consistent, effective delivery of the active ingredient — which oxidation-related subpotency compromises.
What Patients Should Do
- Check the lot number printed on your rosuvastatin or icosapent ethyl bottle against those listed above.
- If your lot number matches, contact your pharmacy — they can verify whether the lot is affected and provide a replacement from unaffected stock at no additional cost.
- Do not stop taking your statin or icosapent ethyl without speaking to your physician or pharmacist. Abruptly stopping statin therapy, in particular, carries risk for patients with established cardiovascular disease. The appropriate response is to switch to a non-recalled lot, not to stop the medication.
- If you have been taking rosuvastatin from the recalled AvKARE lot for an extended period and your next lipid panel shows unexpectedly elevated LDL, mention the recalled lot to your physician — the dissolution issue may partially explain the result, and retesting after switching to an unaffected lot is appropriate.
- For current recall status, check the FDA Drug Recalls database at fda.gov/drugs/drug-safety-and-availability/drug-recalls .
Why Drug Dissolution and Potency Matter
Not all drug recalls involve contamination or carcinogens. A significant category of recalls involves manufacturing process failures that cause the drug to not work properly — either because it does not dissolve and absorb as intended (dissolution failure) or because the active ingredient has degraded before the patient takes it (subpotency).
In cardiovascular medicine, this type of failure is particularly consequential because statins and omega-3 agents are used to manage ongoing, modifiable risk — not to treat acute symptoms. A patient who is taking a subpotent statin may feel exactly the same as always while their LDL is higher than their physician believes. The gap between intended effect and actual effect may only become apparent at the next lipid panel, or in the worst case, through a cardiovascular event.
The Bottom Line
AvKARE's rosuvastatin (Lot 49124, Exp. December 2026) and Zydus's Icosapent Ethyl (lots S2520304, S2520333, S2540186) were both recalled in early 2026 for manufacturing defects that compromise their effectiveness. Check your bottles against these lot numbers, contact your pharmacist for replacements if needed, and do not stop cardiovascular medications without your physician's guidance.
